The Battlefield of Chemotherapy in Pediatric Cancers.
Letao BoYouyou WangYidong LiJohn N D WurpelZoufang HuangZhe-Sheng ChenPublished in: Cancers (2023)
The survival rate for pediatric cancers has remarkably improved in recent years. Conventional chemotherapy plays a crucial role in treating pediatric cancers, especially in low- and middle-income countries where access to advanced treatments may be limited. The Food and Drug Administration (FDA) approved chemotherapy drugs that can be used in children have expanded, but patients still face numerous side effects from the treatment. In addition, multidrug resistance (MDR) continues to pose a major challenge in improving the survival rates for a significant number of patients. This review focuses on the severe side effects of pediatric chemotherapy, including doxorubicin-induced cardiotoxicity (DIC) and vincristine-induced peripheral neuropathy (VIPN). We also delve into the mechanisms of MDR in chemotherapy to the improve survival and reduce the toxicity of treatment. Additionally, the review focuses on various drug transporters found in common types of pediatric tumors, which could offer different therapeutic options.
Keyphrases
- end stage renal disease
- locally advanced
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- multidrug resistant
- radiation therapy
- emergency department
- prognostic factors
- young adults
- squamous cell carcinoma
- oxidative stress
- high glucose
- drug delivery
- chemotherapy induced
- replacement therapy
- climate change